Drug Sponsors

Promedior opens new office and labs in Lexington, Mass.

Monday, December 17, 2012 03:34 PM

Promedior, a clinical stage biotechnology company focused on fibrosis, is opening its new office and laboratory space at 101 Hartwell Avenue, Lexington, Mass.

More... »

Vivalis, Intercell merge to create Valneva

Monday, December 17, 2012 03:06 PM

The management boards of Vivalis, a biopharmaceutical company focused on cell-based solutions, and Intercell, a vaccine-biotechnology company, have agreed to the terms of a merger to create the newly-named Valneva, a European biotechnology company in vaccines and antibodies.

More... »

Teva, Handok to establish business venture in Korean pharma market

Monday, December 17, 2012 01:41 PM

Teva Pharmaceutical Industries, an Israel-based pharmaceutical company, and Handok Pharmaceuticals, a pharmaceutical/healthcare company in Korea, have agreed to establish a business venture in South Korea, allowing Teva to gain entrance into the Korean pharmaceutical market, currently valued at approximately $14 billion.

More... »

Naurex completes $38M Series B financing

Monday, December 17, 2012 12:03 PM

Naurex, an Evanston, Ill.-based clinical-stage company focused on developing treatments for CNS disorders, has completed a $38 million Series B financing led by new investor Baxter Ventures. 

More... »

Catalent, UMN Pharma collaborate on biosimilar development, production in Japan

Monday, December 17, 2012 11:35 AM

Catalent Pharma Solutions, a Somerset, N.J.-based developer of solutions and drug delivery technology, has signed an agreement to provide UMN Pharma, a Japanese pharmaceutical company, a broad range of biosimilar cell lines using Catalent's proprietary GPEx technology.

More... »

Warnex completes sale of bioanalytical services to CRO Biotrial

Monday, December 17, 2012 11:06 AM

Warnex, a life sciences company, has successfully completed the sale of its bioanalytical services division to Biotrial Research, a privately-owned CRO headquartered in France.

More... »

Fresenius to discontinue biotech subsidiary

Friday, December 14, 2012 01:27 PM

Fresenius, a health care group with international operations, has decided to discontinue its subsidiary Fresenius Biotech. Instead, the company will focus on its four established business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, which offer significant growth opportunities.

More... »

Biocartis completes $44.5M series D funding

Friday, December 14, 2012 11:12 AM

Biocartis, a molecular diagnostics company developing and commercializing high quality, easy to use platforms and clinically relevant oncology assays, has completed a $44.5 million Series D equity funding entirely backed by existing investors.

More... »

The Medicines Company to acquire Incline Therapeutics

Friday, December 14, 2012 10:14 AM

The Medicines Company, a medical solutions company based in Parsippany, N.J., has agreed to acquire Incline Therapeutics, hospital-focused specialty pharmaceutical company based in Redwood City, Calif.

More... »

Galderma to acquire Spirig Pharma

Wednesday, December 12, 2012 02:31 PM

Galderma Pharma, a Switzerland-based global specialty pharmaceutical company focused on dermatology, has entered into a definitive agreement to acquire Spirig Pharma, a Swiss company that develops, produces, and markets dermatological products.

More... »